“Should US public pension plans continue to exceed expectations, with technological growth persisting as new technologies mature, and the Fed’s rates stabilize, we could see market gains and improved funding for these plans,” analysts led by Todd Kanaster

STT stock has moved up 13.3% YTD, outpacing peers, with growth fueled by acquisitions, fee gains and shareholder rewards.

Housing Numbers Come in Mixed.

IWM is gaining momentum as rate-cut hopes, attractive valuations and rising small-business optimism fuel renewed interest in small-cap ETFs.

Tesla’s spot in the S&P 500 could reshape your portfolio. Discover four key ways this move affects investors and market dynamics in 2025.

The dollar index (DXY00 ) today is down by -0.08%. The dollar is under pressure today from lower T-note yields. Also, signs of progress in peace talks over Ukraine are boosting EUR/USD at the expense of the dollar. Losses in the dollar are limited due to

Five dividend growth stocks, AGCO, VRT, TEL, CAH and WWD, stand out for their steady payouts, strong fundamentals and long-term upside potential.

The U.S. government aims to take an equity stake in Intel, Commerce Secretary Howard Lutnick said Tuesday morning.“We should get an equity stake for our money, so we’ll deliver the money which was already committed under the Biden administration,” Lutnick

Despite Deere & Company’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.52%. September E-mini S&P futures (ESU25 ) are down -0.13%, and September...

ETFs pulled in $38B last week, led by QQQ, VOO, ARKK, ETHA and VCIT as cooling inflation and rate-cut hopes boosted markets.

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does in

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.